Clinical trials: Geriatric Cancer Patients
Lung Cancer Patients
Global, Regional, and National Burdens and Trends of Tracheal, Bronchial, and Lung Cancer in Individuals Aged 70 Years and Older from 1990 to 2021
Despite the increasing health burden of tracheal, bronchial, and lung (TBL) cancer patients aged ≥ 70 years worldwide, data on its burden and trends are limited.
- Trial name
- GDBlung70 (NCT06694194)
- Volunteers
- 111,627 people
- Sponsor
- Hongquan Xing
Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
This phase II trial is studying how well a frailty index and geriatric assessment works in predicting toxicity to front-line chemotherapy in treating patients with stage IV non-small cell lung cancer.
- Trial name
- NCT01026467
- Testing
- cisplatin, carboplatin, questionnaire administration
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Wake Forest University Health Sciences
Malignant Haemopathies, Acute Leukemia
Unicentric Retrospective Analysis of a Cohort of 602 Young Adult and Adolescent Patients (AJA), Aged 15 to 30 Years, With Haematological Malignancies, and Managed Between 2000 and 2016
Unicentric retrospective analysis of a cohort of 602 young adult and adolescent patients, aged 15 to 30 years, with haematological malignancies, and managed between 2000 and 2016
- Conditions
- Malignant Haemopathies, Acute Leukemia, Non-hodgkin Lymphoma, Hodgkin Lymphoma
- Trial name
- HEMAJA (NCT03469921)
- Testing
- administered therapeutic regimens
- Where
- France
- Volunteers
- 602 people
- Sponsor
- Institut Paoli-Calmettes
Colon Cancer, Frailty
Optimised Post-discharge Care in Older Patients After Surgery for Colon Cancer (ERAS 3.0)
The purpose of the study is to investigate whether an extended program (ERAS 3.0) initiated hospital discharge, can improve recovery in elderly, frail patients who have undergone surgery for colon cancer.
- Trial name
- NCT06802991
- Testing
- ERAS 3.0 (Enhanced Recovery After Surgery)
- Where
- 2 sites in Denmark
- Volunteers
- 60 people
- Sponsor
- Copenhagen University Hospital at Herlev
Leukemia
"AIDA" Protocol (LAP 0493)
The main purposes of the AIDA protocol are to test the role of intermittent maintenance therapy with ATRA, standard maintenance chemotherapy with methotrexate and 6-mercaptopurine of both in PCR negative patients at the end of…
- Trial name
- NCT01064557
- Testing
- all-trans retinoic acid (ATRA)
- Where
- 80 sites in Belgium, Germany and 3 more
- Volunteers
- 1,068 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Multiple Myeloma
eHealth for the Elderly
Since internet usage as a complementing element in cancer care is becoming more and more important in oncological routine we launched My-eStEPs (eHealth Strategy for Elderly Patients with Multiple Myeloma) to investigate how…
- Trial name
- My-eStEPs (NCT04393090)
- Testing
- eHealth platform CANKADO
- Where
- 8 sites in Germany
- Volunteers
- 30 people
- Sponsor
- Cankado GmbH
Acute Myeloid Leukemia
Treatment With Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) With Acute Myeloid Leukemia: A Single Institution Experience.
The treatment of very elderly patients (≥70 years) with acute myeloid leukemia remains controversial. Although the outcome in younger adults has improved because of cytarabine- and anthracycline-based chemotherapy with advanced…
- Trial name
- NCT03350152
- Where
- France
- Volunteers
- 302 people
- Sponsor
- Hospices Civils de Lyon
Precursor Cell Lymphoblastic Leukemia-lymphoma
Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy)
The purpose of this study is to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), safety and toxicity, and pharmacokinetics (PK) of ixazomib administered intravenously in combination with…
- Trial name
- NCT03888534
- Testing
- Ixazomib
- Where
- 7 sites in United States, Spain
- Sponsor
- Millennium Pharmaceuticals, Inc.
Colorectal Cancer
Advanced Geriatric Evaluation and Quality of Life in Colorectal Cancer Surgery
Colorectal cancer (CRC) disproportionately affects patients aged 70 years and older. Surgery is the main treatment modality for CRC, but is associated with increased risk of postoperative morbidity, disability and loss of health…
- Trial name
- AGE CRC (NCT04443816)
- Where
- 6 sites in Netherlands
- Volunteers
- 273 people
- Sponsor
- St. Antonius Hospital
Non-small Cell Lung Cancer (NSCLC) Stage IV, Locally Advanced Non-Small Cell Lung Cancer
An Exploratory Clinical Study Of Bempemab Combined With Anlotinib As First-Line Treatment For Elderly Patients With Locally Advanced Or Metastatic Non-Small-Cell Lung Cancer
This exploratory clinical study evaluates the efficacy and safety of combining benmelstobart (a PD-L1 inhibitor) with anlotinib (a multi-target anti-angiogenic TKI) as a first-line, chemotherapy-free treatment for elderly…
- Conditions
- Non-small Cell Lung Cancer (NSCLC) Stage IV, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
- Trial name
- BEACON-OLD (NCT07849712)
- Testing
- Benmelstobart Combined With Anlotinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Cancer Hospital
Pancreatic Ductal Adenocarcinoma
Survival Among Patients With Pancreatic Cancer Depending on Surgical Resection Rate
The primary aim of this population-based study is to investigate how a high resection rate of pancreaticoduodenectomy affects overall survival among patients aged ≥70 years with pancreatic ductal adenocarcinoma.
- Trial name
- NCT04802993
- Testing
- Resection rates
- Volunteers
- 5,123 people
- Sponsor
- Linkoeping University
Ewing's Sarcoma/Soft Tissue Sarcoma, Neuroblastoma
A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone
This is a multi-site study with plerixafor in pediatric cancer patients. The study will be conducted in 2 stages: Stage 1 is a dose-escalation study.
- Conditions
- Ewing's Sarcoma/Soft Tissue Sarcoma, Neuroblastoma, Brain Tumors
- Trial name
- NCT01288573
- Testing
- plerixafor
- Where
- 27 sites in Belgium, Czechia and 10 more
- Volunteers
- 46 people
- Sponsor
- Genzyme, a Sanofi Company
Bone Metastases of a Malignant Tumor, Metastatic Bone Tumor
Hemiarthroplasty for Elderly With Proximal Humeral Mets
Bone metastases are common in patients with advanced cancer and frequently involve the proximal humerus, leading to severe pain and loss of shoulder function.
- Trial name
- PHM-HA (NCT07471022)
- Testing
- Proximal Humeral Hemiarthroplasty
- Volunteers
- 53 people
- Sponsor
- Sichuan Provincial People's Hospital
Rectal Cancer
Early-onset Rectal Cancer
The present study aimed to review the characteristics and outcome of early-onset rectal cancer in a subset of Egyptian patients aged 40 years or less.
- Trial name
- NCT04496765
- Testing
- Total mesorectal excision
- Where
- Egypt
- Volunteers
- 244 people
- Sponsor
- Mansoura University
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00022633
- Testing
- gemcitabine hydrochloride, paclitaxel
- Where
- 92 sites in United States
- Volunteers
- 65 people
- Sponsor
- SWOG Cancer Research Network
Gastric Cancer
Handgrip Strength (HGS) With HGS Asymmetry Are Associated With All-cause Mortality and Hospital Readmissions
Adding the handgrip strength (HGS) asymmetry to the existing measurements of low HGS may improve the assessment of muscle function.
- Trial name
- NCT05397444
- Testing
- No intervention
- Where
- China
- Volunteers
- 342 people
- Sponsor
- Nanjing Medical University